中央社訊息平台
歡迎公司行號投遞新聞訊息！詳洽業務行銷中心 人工服務時間為週一至週六9:30-12:00、14:00-18:30 如有週日發稿需求請於週六18:00前完成刊登程序。

更多訊息

NYCU to Establish AB-BNCT Center to Expand Taiwan’s Cancer Precision Medicine Capacity

發稿時間：2026/01/08 14:16:57

(中央社訊息服務20260108 14:16:57)National Yang Ming Chiao Tung University (NYCU) is advancing Taiwan's capacity for next-generation cancer treatment. NYCU has announced plans to introduce an Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) system at the under-construction Chuming Hospital on the Boai Campus — expanding access to cutting-edge precision radiotherapy for patients across Taiwan.

On January 7, NYCU President Chi-Hung Lin, Heron Neutron Medical Corp. Chairman Chi-Rung Hsu, and Chuming Foundation CEO Tsai-Wu Liu signed a memorandum of intent for industry–academia–medical collaboration.
On January 7, NYCU President Chi-Hung Lin, Heron Neutron Medical Corp. Chairman Chi-Rung Hsu, and Chuming Foundation CEO Tsai-Wu Liu signed a memorandum of intent for industry–academia–medical collaboration.

The partners will jointly establish the AB-BNCT Center, integrating critical resources across research, engineering, and clinical care to deliver high-quality, evidence-based cancer treatment and to build a globally competitive medical and research platform.

The Boai Campus AB-BNCT system will become NYCU's second such installation, following the university's first system currently operating at Taipei Veterans General Hospital (TVGH). AB-BNCT works by administering boron-containing compounds that selectively accumulate in tumor cells; a precisely targeted neutron beam then triggers a reaction inside the cancer cells, destroying them while sparing surrounding healthy tissue. The technology is recognized as one of today's most advanced forms of precision oncologic radiotherapy.

The planned center will integrate two key medical innovations — boron neutron capture therapy and ultra-high-field magnetic resonance imaging (MRI). By combining high-resolution diagnostic imaging, longitudinal treatment-tracking tools, and precision radiation delivery systems, the center aims to enhance treatment planning, response evaluation, and patient safety, offering more personalized, higher-quality cancer care.

Boron Neutron Capture Therapy (BNCT) is a cell-level, targeted form of radiotherapy. It works by delivering boron compounds to tumor cells and then exposing them to a neutron beam, which triggers a reaction that releases energy to destroy the cancer cells while sparing surrounding healthy tissue. (Photo credit: Heron Neutron Medical Corp.)
Boron Neutron Capture Therapy (BNCT) is a cell-level, targeted form of radiotherapy. It works by delivering boron compounds to tumor cells and then exposing them to a neutron beam, which triggers a reaction that releases energy to destroy the cancer cells while sparing surrounding healthy tissue. (Photo credit: Heron Neutron Medical Corp.)

The collaboration leverages Heron Neutron Medical Corp.'s expertise in independently developed AB-BNCT accelerator systems and engineering integration, together with Chuming Hospital's future clinical applications. The three parties will co-create a comprehensive ecosystem spanning basic research, system and equipment development, clinical validation, and real-world medical services — fully realizing a patient-centered model of precision radiotherapy.

Once established, the AB-BNCT Center will serve simultaneously as a treatment hub, clinical development platform, and research base. By systematically advancing BNCT applications across multiple cancer types and strengthening collaboration among academia, industry, and healthcare partners, the center will shorten the translation pathway from innovation to clinical practice while ensuring treatment quality, safety, and therapeutic benefit.

The initiative marks a significant step in reinforcing Taiwan's leadership in precision radiotherapy and advanced medical technologies — and in delivering tangible benefits to cancer patients nationwide.